The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
Publications
Fatal, gold-induced pneumonitis.
Rheumatology international. 2003;23(4):207-10
Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation.
Intensive care medicine. 1998;24(10):1110-2
Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease.
American journal of respiratory and critical care medicine. 1997;155(3):1011-20
Reversal of progressive, life-threatening gold hypersensitivity pneumonitis by corticosteroids.
The American journal of medicine. 1981;71(5):908-12
Relationship of gold and penicillamine therapy to diffuse interstitial lung disease.
Annals of the rheumatic diseases. 1981;40(2):136-41
Interleukin 2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role.
Acta oto-laryngologica. 1992;112(2):370-5
Diffuse pulmonary injury associated with gold treatment.
The New England journal of medicine. 1976;294(17):919-21